Cargando…
The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia
Massive obstetric haemorrhage remains a major cause of maternal death attributable to hypofibrinogenaemia. Transfusion of large volumes of fresh frozen plasma (FFP) is required to normalise fibrinogen levels. We compared the efficacy of FFP (F group) with that of FFP plus fibrinogen concentrate (F +...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402272/ https://www.ncbi.nlm.nih.gov/pubmed/28436465 http://dx.doi.org/10.1038/srep46749 |
_version_ | 1783231195532754944 |
---|---|
author | Matsunaga, Shigetaka Takai, Yasushi Nakamura, Eishin Era, Sumiko Ono, Yoshihisa Yamamoto, Koji Maeda, Hiroo Seki, Hiroyuki |
author_facet | Matsunaga, Shigetaka Takai, Yasushi Nakamura, Eishin Era, Sumiko Ono, Yoshihisa Yamamoto, Koji Maeda, Hiroo Seki, Hiroyuki |
author_sort | Matsunaga, Shigetaka |
collection | PubMed |
description | Massive obstetric haemorrhage remains a major cause of maternal death attributable to hypofibrinogenaemia. Transfusion of large volumes of fresh frozen plasma (FFP) is required to normalise fibrinogen levels. We compared the efficacy of FFP (F group) with that of FFP plus fibrinogen concentrate (F + F group) in massive obstetric haemorrhage. In this retrospective study, we compared the medical charts (2004–2016) of 137 patients with <150 mg/dl fibrinogen treated with F + F (n = 47; after August 2009) or F (n = 56; before August 2009). Although fibrinogen concentrate was only administered in severe cases, the FFP/red blood cell concentrate (RCC) ratio was significantly lower in the F + F group than in the F group. A sub-group analysis of cases requiring ≥18 RCC units showed that the F + F group received significantly less FFP than the F group (40.2 ± 19.6 versus 53.4 ± 18.5 units; P = 0.047) and showed significantly less pulmonary oedema (24.0% vs 57.1%; P < 0.05) in the absence of any significant differences in pre-transfusion coagulation, estimated blood loss, or RCC transfusion volume. Administration of fibrinogen concentrate increased the rate of fibrinogen supplementation five-fold and reduced FFP dosage, the FFP/RCC ratio, and the incidence of pulmonary oedema. |
format | Online Article Text |
id | pubmed-5402272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-54022722017-04-26 The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia Matsunaga, Shigetaka Takai, Yasushi Nakamura, Eishin Era, Sumiko Ono, Yoshihisa Yamamoto, Koji Maeda, Hiroo Seki, Hiroyuki Sci Rep Article Massive obstetric haemorrhage remains a major cause of maternal death attributable to hypofibrinogenaemia. Transfusion of large volumes of fresh frozen plasma (FFP) is required to normalise fibrinogen levels. We compared the efficacy of FFP (F group) with that of FFP plus fibrinogen concentrate (F + F group) in massive obstetric haemorrhage. In this retrospective study, we compared the medical charts (2004–2016) of 137 patients with <150 mg/dl fibrinogen treated with F + F (n = 47; after August 2009) or F (n = 56; before August 2009). Although fibrinogen concentrate was only administered in severe cases, the FFP/red blood cell concentrate (RCC) ratio was significantly lower in the F + F group than in the F group. A sub-group analysis of cases requiring ≥18 RCC units showed that the F + F group received significantly less FFP than the F group (40.2 ± 19.6 versus 53.4 ± 18.5 units; P = 0.047) and showed significantly less pulmonary oedema (24.0% vs 57.1%; P < 0.05) in the absence of any significant differences in pre-transfusion coagulation, estimated blood loss, or RCC transfusion volume. Administration of fibrinogen concentrate increased the rate of fibrinogen supplementation five-fold and reduced FFP dosage, the FFP/RCC ratio, and the incidence of pulmonary oedema. Nature Publishing Group 2017-04-24 /pmc/articles/PMC5402272/ /pubmed/28436465 http://dx.doi.org/10.1038/srep46749 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Matsunaga, Shigetaka Takai, Yasushi Nakamura, Eishin Era, Sumiko Ono, Yoshihisa Yamamoto, Koji Maeda, Hiroo Seki, Hiroyuki The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia |
title | The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia |
title_full | The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia |
title_fullStr | The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia |
title_full_unstemmed | The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia |
title_short | The Clinical Efficacy of Fibrinogen Concentrate in Massive Obstetric Haemorrhage with Hypofibrinogenaemia |
title_sort | clinical efficacy of fibrinogen concentrate in massive obstetric haemorrhage with hypofibrinogenaemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402272/ https://www.ncbi.nlm.nih.gov/pubmed/28436465 http://dx.doi.org/10.1038/srep46749 |
work_keys_str_mv | AT matsunagashigetaka theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT takaiyasushi theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT nakamuraeishin theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT erasumiko theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT onoyoshihisa theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT yamamotokoji theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT maedahiroo theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT sekihiroyuki theclinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT matsunagashigetaka clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT takaiyasushi clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT nakamuraeishin clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT erasumiko clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT onoyoshihisa clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT yamamotokoji clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT maedahiroo clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia AT sekihiroyuki clinicalefficacyoffibrinogenconcentrateinmassiveobstetrichaemorrhagewithhypofibrinogenaemia |